--- title: 'Executive Director, Key Accounts Lead at Summit Therapeutics' canonical: 'https://feeny.ai/job/executive-director-key-accounts-lead-summit-therapeutics-field-fcy78qbyss0k' type: 'job' last_seen: '2026-10-30' --- # Executive Director, Key Accounts Lead at Summit Therapeutics - **Company:** Summit Therapeutics - **Location:** Field, United States - **Compensation:** $228k–$285k - **Work type:** remote - **Posted:** 2026-10-20 - **Last confirmed live:** 2026-10-30 - **Apply:** https://job-boards.greenhouse.io/summittherapeutics/jobs/4459147009 ## Job description About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role: As a key member of the Market Access leadership team, the Executive Director, Key Accounts leader will help lead the preparation, development, and execution of market access account strategies.. This is a critical customer facing role to helping to ensure broad access, reimbursement, and patient affordability. The individual will be responsible for building and maintaining relationships with key oncology stakeholders, including Specialty GPOs/Aggregators, Oncology Supergroups, Key Community Oncology practices, IDNs, Guideline and Pathway organizations. Additionally, the Executive Director, Key Accounts will lead the Key Accounts field account team and collaborate closely with Payer Strategic Accounts and sales teams, as well as internal teams, to integrate customer and market insights into pricing, contracting, and market access strategies and plans. Role and Responsibilities: - Team Leadership: Build, train, and lead the account management field team (GPOs, Community Oncology, IDNs, and other Access Stakeholders) to develop and execute strategic business plans that align with overall objectives, maximize product access, and ensure reimbursement. - Stakeholder Engagement: Establish and maintain relationships with key decision-makers, including Formulary, P&T, and Pathway leaders, Medical & Pharmacy Directors and other population-based stakeholders to secure appropriate access and optimal product positioning. - Leadership and Influence: Demonstrate leadership among various customer groups and Access stakeholders, including GPOs, Community Oncology practices, IDNs, Pathway Committee members, and others (State Societies, COA, NCODA, etc.). - Cross-functional Collaboration: Partner with internal teams (Market Access, Medical Affairs, HEOR, Commercial Operations, Regulatory, Legal, Finance, Marketing, Sales, etc.) to address reimbursement challenges and develop coordinated solutions that are compliant and effective. - Strategy Development: Co-create strategies, tools, and tactics for the field team to communicate the product value proposition effectively and mitigate access barriers. Collaborate on pricing and contracting strategies, HEOR evidence generation plans, patient support programs, payer marketing initiatives, and account management approaches. - Alignment and Negotiation: Lead discussions with internal and external partners to ensure alignment on access, coverage, and reimbursement strategies. - Culture and Performance: Foster a high-performance culture within the field team by promoting accountability, urgency, partnership & collaboration, ethical behavior, and professional development. - Industry Insight: Stay informed on healthcare industry trends, payer policies, reimbursement processes, and competitive activity. Provide strategic insights to inform decision-making, access strategies, and product launches. - Compliance: Ensure all Market Access initiatives are developed and executed in compliance with legal, regulatory, and ethical standards. - All other duties as assigned Experience, Education and Specialized Knowledge and Skills: - Bachelor’s degree in business, healthcare, or a related field; advanced degree preferred. - Minimum of 15+ years of experience in payer and/or GPO strategy, pricing, and reimbursement within the pharmaceutical industry - Minimum of 7+ years of focused account management experience in the oncology access marketplace - Demonstrated success in engaging with GPOs, Oncology Aggregator’s, Community Oncology Practices, and IDNs - Strong understanding of the US healthcare payer/access landscape and regulatory environment - Excellent strategic thinking, leadership, negotiation, and relationship management skills - Ability to lead cross-functional teams and drive complex projects to completion - Exceptional communication and presentation skills - Successful record of achieving and maintaining compliance with all applicable regulatory, legal, and operational rules - Proven ability to work effectively in a fast-pace and dynamic environment, balancing multiple priorities and meeting deadlines. - Travel: Ability to travel to support business priorities as needed This is the pay for this position Pay Transparency $228,000—$285,000 USD Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation. Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit. Summit Therapeutics Inc. is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. ## About Summit Therapeutics ## Company Overview - **One-liner**: Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on discovering, developing, and commercializing novel bispecific antibody therapies, with its lead candidate ivonescimab targeting PD-1 and VEGF for multiple solid tumors. - **Entity Type**: Public (NASDAQ: SMMT) - **Headquarters**: Miami, Florida, USA (with additional offices in Palo Alto, CA; Princeton, NJ; Oxford, UK; and Dublin, Ireland) - **Founded**: 2003 - **Founders**: Not publicly disclosed on the company website; the company was founded in 2003. ## Core Business - **Primary industry**: Biopharmaceuticals / Oncology - **Target customers**: B2B (healthcare providers, patients, and caregivers) with a focus on resolving serious unmet medical needs in oncology - **Mission statement**: "To resolve serious, unmet medical needs for the betterment of overall human health." [smmttx.com](https://smmttx.com/company/about-us/default.aspx) ## Products & Services - **Ivonescimab (SMT112)**: A novel, potential first-in-class investigational bispecific antibody targeting both PD-1 and VEGF. It is designed to combine immunotherapy (PD-1 blockade) with anti-angiogenesis (VEGF blockade) into a single molecule. Currently being studied in several global Phase 3 clinical trials for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC). Licensed from Akeso, Inc. (HKEX: 9926.HK) for territories including the U.S., Canada, Europe, Japan, Latin America, the Middle East, and Africa. [smmttx.com](https://smmttx.com/pipeline/default.aspx) ## Market Standing - **Valuation/Market Cap**: Approximately $2.7 billion (as of recent data) [linkedin.com](https://www.linkedin.com/company/summit-therapeutics) - **Key Metric**: Annual revenue of approximately $705,000 (reported). The company is pre-commercialization and heavily investing in R&D. Total funding raised since IPO (2015) is not disclosed, but the company has a strong cash position from equity offerings. - **Notable Investors/Partners**: Akeso, Inc. (key licensing partner for ivonescimab). The company is publicly traded with institutional and retail investors. - **Growth Signals**: - Headcount grew 72.5% year-over-year to 244 employees. [linkedin.com](https://www.linkedin.com/company/summit-therapeutics) - Multiple global Phase 3 trials actively recruiting (HARMONi, HARMONi-3, HARMONi-7, HARMONi-GI3, ILLUMINE). - Over 4,000 patients have been treated with ivonescimab across all clinical trials globally. [smmttx.com](https://smmttx.com/pipeline/default.aspx) - Achieved Great Place to Work® Certification. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx) ## Competitive Advantages - **Novel Mechanism**: Ivonescimab is a first-in-class bispecific antibody targeting both PD-1 and VEGF simultaneously, potentially offering superior efficacy and fewer side effects compared to combination therapies. - **Speed and Execution**: The company emphasizes "high-speed execution in commercialization" and has rapidly initiated multiple Phase 3 trials. - **Global Reach**: Licensed territories cover major markets (U.S., Canada, Europe, Japan, Latin America, Middle East, Africa) with a strong partner (Akeso) in the rest of the world. - **Strong Balance Sheet**: With a $2.7B market cap and public listing, the company has access to capital markets to fund its pipeline. ## Strategic Focus - **Current priorities**: Advancing ivonescimab through Phase 3 clinical trials across multiple solid tumor indications (NSCLC, CRC, HNSCC), with the goal of regulatory approval and commercialization. - **Future direction**: Expanding the pipeline into additional solid tumors and leveraging the bispecific platform for future therapies. The company is focused on becoming a leading oncology player. - **Near-term milestones**: Data readouts from ongoing Phase 3 trials, potential regulatory submissions, and building commercial infrastructure. ## Why Work Here - **Culture**: The company has achieved Great Place to Work® Certification, indicating a positive, supportive, and fulfilling work environment. Core values include Commitment to People, Integrity, Passion for Excellence, Purposeful Urgency, Accountability, and Collaboration. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx) - **Work Environment**: Fast-paced, high-energy atmosphere focused on innovation and collaboration. The company emphasizes "making a significant difference in patients’ lives." - **Benefits (U.S.)**: - 401(k) with 6% employer match - Employee Stock Purchase Plan (ESPP) with 15% discount up to the annual federal limit - Flexible Spending Account - Commuter Benefit - Onsite lunch provided - **Benefits (U.K.)**: - Private Medical Insurance - Employee Assistance Program - Life Assurance Policy - Company Pension Contributions - ESPP - **Remote/Hybrid Policy**: Not explicitly stated, but multiple office locations suggest a hybrid or on-site presence is expected for many roles. - **Open Roles**: 25 active job postings (as of recent data) including Senior Director of Sales Operations, Clinical Scientists, Medical Science Liaisons, and Drug Product MSAT roles. [greenhouse.io](https://job-boards.greenhouse.io/summitherrapeutics) - **Headcount Growth**: 72.5% year-over-year growth signals a scaling organization with opportunities for career advancement. ## Sources 1. [smmttx.com - About Us](https://smmttx.com/company/about-us/default.aspx) 2. [smmttx.com - Investor Relations Overview](https://www.smmttx.com/overview/default.aspx) 3. [smmttx.com - Pipeline](https://smmttx.com/pipeline/default.aspx) 4. [smmttx.com - Careers Overview](https://smmttx.com/careers/careers-overview/default.aspx) 5. [linkedin.com - Summit Therapeutics Company Page](https://www.linkedin.com/company/summit-therapeutics) 6. [greenhouse.io - Summit Therapeutics Careers](https://job-boards.greenhouse.io/summitherrapeutics) ## Other roles at Summit Therapeutics - [Director, MSAT-Drug Product (US, UK, Ireland, or Switzerland)](https://feeny.ai/job/director-msat-drug-product-us-uk-ireland-or-switzerland-summit-therapeutics-r3tyakx42enr) — Princeton, NJ - [Senior Medical Science Liaison (Upper NY)](https://feeny.ai/job/senior-medical-science-liaison-upper-ny-summit-therapeutics-new-york-0m9ztt6s208s) — New York, NY - [Medical Writer, Medical Communications & Publications](https://feeny.ai/job/medical-writer-medical-communications-publications-summit-therapeutics-palo-alto-mq4p6tvcrxnt) — Palo Alto, CA - [Director, Medical Affairs Operations](https://feeny.ai/job/director-medical-affairs-operations-summit-therapeutics-princeton-qnwcxs9r0125) — Princeton, NJ - [Senior Manager, Externally Sponsored Research](https://feeny.ai/job/senior-manager-externally-sponsored-research-summit-therapeutics-palo-alto-h6g4ymrm7ret) — Palo Alto, CA - [Paralegal](https://feeny.ai/job/paralegal-summit-therapeutics-palo-alto-7crgxyrgt8ht) — Palo Alto, CA - [Director, Regulatory Affairs CMC](https://feeny.ai/job/director-regulatory-affairs-cmc-summit-therapeutics-remote-spf3wfkhxryb) - [Senior Director, Commercial Excellence](https://feeny.ai/job/senior-director-commercial-excellence-summit-therapeutics-princeton-7yyt2trazq5s) — Princeton, NJ - [Senior Director, National Field Excellence](https://feeny.ai/job/senior-director-national-field-excellence-summit-therapeutics-united-states-tbfnrz5523j2) — United States - [Associate Director, Site Alliances and Strategy](https://feeny.ai/job/associate-director-site-alliances-and-strategy-summit-therapeutics-remote-k0p2pnwxn3bb)